Hagar H. Fahim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hagar H. Fahim has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Abdallah M. Gameel
Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo 11796, Egypt
1 shared publication - Ahmed Sayed Abddel-Moneim
Department of Microbiology and Immunology, College of Medicine and Health Sciences Sultan Qaboos University Muscat Oman
1 shared publication Asmaa Abo-Bakr
Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt
1 shared publication- Brian Thomas Layden
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine University of Illinois Chicago Chicago Illinois USA
1 shared publication Gehan Safwat
Faculty of Biotechnology, October University for Modern Sciences and Arts, Giza, Egypt
1 shared publication- Ghada Mohamed
Department of pathology, National Cancer Institute, Cairo University, Egypt
1 shared publication
Latest Publications
- Open Access
Aiding Cancer’s “Sweet Tooth”: Role of Hexokinases in Metabolic Reprogramming
Hexokinases (HKs) convert hexose sugars to hexose-6-phosphate, thus trapping them inside cells to meet the synthetic and energetic demands. HKs participate in various standard and altered physiological processes, including cancer, primarily through the reprogramming of cellular metabolism. Four canonical HKs have been identified with different expression patterns across tissues. HKs 1–3 play a role in glucose utilization, whereas HK 4 (glucokinase, GCK) also acts as a glucose sensor. Recently, a novel fifth HK, hexokinase domain containing 1 (HKDC1), has been identified, which plays a role in whole-body glucose utilization and insulin sensitivity. Beyond the metabolic functions, HKDC1 is differentially expressed in many forms of human cancer. This review focuses on the role of HKs, particularly HKDC1, in metabolic reprogramming and cancer progression.
Open AccessAiding Cancer’s “Sweet Tooth”: Role of Hexokinases in Metabolic Reprogramming
Hexokinases (HKs) convert hexose sugars to hexose-6-phosphate, thus trapping them inside cells to meet the synthetic and energetic demands. HKs participate in various standard and altered physiological processes, including cancer, primarily through the reprogramming of cellular metabolism. Four canonical HKs have been identified with different expression patterns across tissues. HKs 1–3 play a role in glucose utilization, whereas HK 4 (glucokinase, GCK) also acts as a glucose sensor. Recently, a novel fifth HK, hexokinase domain containing 1 (HKDC1), has been identified, which plays a role in whole-body glucose utilization and insulin sensitivity. Beyond the metabolic functions, HKDC1 is differentially expressed in many forms of human cancer. This review focuses on the role of HKs, particularly HKDC1, in metabolic reprogramming and cancer progression.
- 1 June 2021
- Published by Elsevier in Clinical Breast Cancer
- Vol. 21 (3) , e177-e188
HSP70 as a Diagnostic and Prognostic Marker in Egyptian Women With Breast Cancer
- 1 June 2021
- Published by Elsevier in Clinical Breast Cancer
- Vol. 21 (3) , e177-e188
HSP70 as a Diagnostic and Prognostic Marker in Egyptian Women With Breast Cancer